Physician profile
Deepa Amberker
NPI 1154685592
$3,546.94
in general payments reported to CMS, 2019-2025
22 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $176 · 2021: $39.14 · 2022: $759 · 2023: $615 · 2024: $815 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047 · Education: $4.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.61 |
| Education | $4.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $722.97 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $364.92 | 2022-2023 | Jesduvroq |
| Opko Pharmaceuticals, LLC | $286.86 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $239.94 | 2020-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $224.03 | 2023-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $217.60 | 2022-2025 | |
| Horizon Therapeutics Plc | $214.37 | 2022-2023 | Krystexxa |
| Amgen INC. | $169.32 | 2022-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.21 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $136.87 | 2022 | |
| Calliditas Therapeutics US INC. | $132.37 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $126.76 | 2023-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Travere Therapeutics, INC. | $116.90 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $91.74 | 2019-2025 | Vafseo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $76.91 | 2019-2021 | |
| Lilly USA, LLC | $58.56 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $43.64 | 2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $40.20 | 2025 | |
| Ardelyx, INC. | $13.77 | 2025 | Ibsrela |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Amberker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.